I
ImmunArray
Biotech & Life Sciences · Rehovot, Israel · Founded 2006
A molecular diagnostics company MoreLess
ImmunArray is a clinically driven company specializing in molecular diagnostic tests designed to support the diagnosis and prognosis of complex medical conditions. The company primarily serves healthcare providers, including rheumatologists and neurologists, by offering innovative diagnostic solutions. Operating in the medical diagnostics market, ImmunArray focuses on developing assays and multiplex tests that enhance patient triage and treatment decisions. Their flagship product, 'Talk to Us,' is a diagnostic test that helps rule out Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease. Additionally, their BRAINBox program aims to improve the diagnosis and prognosis of brain injuries, including both acute traumatic brain injury (TBI) and chronic phases.
ImmunArray's business model revolves around the development and commercialization of these diagnostic tests, generating revenue through the sale of test kits and related services to healthcare institutions. The company collaborates with various partners and stakeholders in the healthcare sector to advance its research and product offerings.
Keywords: Molecular diagnostics, Systemic Lupus Erythematosus, SLE, brain injury, TBI, assays, multiplex tests, healthcare providers, patient triage, clinical rheumatology.
Company overview
ImmunArray company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2006
- Headquarters
- Rehovot, Israel
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 26.3
Valuation & funding
ImmunArray funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2016 | $10M | $40M | Exigent Capital | ↗ |
| SPINOUTOther financing | Jan 2006 | $0 | — | Weizmann Institute of Science | — |
Growth signals
ImmunArray website traffic
Latest recorded traffic for ImmunArray is 50 monthly website visits, down 75% over the last three months.
Comparisons
ImmunArray compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ImmunArray's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on ImmunArray's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where ImmunArray has talent and traffic
In the news
Latest news about ImmunArray
Recent press, funding announcements, and product moves mentioning ImmunArray — open to read from the original sources.
Market sentiment
What the market is saying about ImmunArray
An AI-synthesized read of the highest-engagement posts about ImmunArray on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmunArray’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.